Back To: Home : Featured Technology : Functional Genomic Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Shipp to lead Verigene push
August 2005
by Chris Anderson  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

NORTHBROOK, Ill.—Nanotechnology life sciences company Nanosphere Inc. recently announced the hiring of Gregory Shipp, M.D., as vice president of medical affairs to spearhead the company's commercialization efforts of its Verigene genomic and proteomic diagnostic tool.
 
According to the company, the Verigene system can simultaneously provide ultra-sensitive genomic and proteomic testing on a single instrument on a scale five to six times more sensitive than current standards.
 
Positioned primarily as a diagnostic tool, Verigene has the potential to aid treatment of recurrent cancer or neurodegenerative diseases. "The potential for the greatest payback is where there is recurrent or very slow onset disease such as cancer," says William Moffitt, president and CEO.
 
Shipp's role with the company is to consult with physicians to "be a voice in the community and to understand their needs," he says.
 
In addition to its diagnostic application, Moffitt says Verigene, because of its high sensitivity can also provide valuable information to researchers in early drug discovery to provide information about particular peptide sequences or biomarkers.
 
Code: E080517

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.